Company profile
Nuformix - Solid Form Discovery
Nuformix Technologies Limited is a UK company with status active founded in 2007 based in London.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MDY0NjUzMWFkaXF6a2N4
Published 23 Oct 2024 08:43
Company registered at Companies House
1 Jun 2015 to 31 Mar 2016
The project will evaluate the feasibility of inhaled delivery of a cocrystal-enabled known drug to treat idiopathic pulmonary fibrosis (IPF) in-vivo. The 1st therapies for IPF - a growing disease (5000 UK patients diagnosed/year*) with high mortality (50% die in 2-3 years of diagnosis*) were approved in 2014 (Pirfenidone & Nintedanib). These new therapies...
1 Feb 2014 to 31 Jul 2015
Nuformix and Vectura will explore pre-competitive applications for the use of cocrystal technology within inhalation formulation and product development for the treatment of respiratory disease. It is hoped the output will provide indications for future product development opportunities and TSB funding will accelerate that process.
1 Nov 2009 to 30 Sep 2012
The CODE-PM project represents a new approach to drug development. The aim of CODE-PM is to generate high-value Intellectual Property (IP) in the emerging field of pharmaceutical cocrystals for subsequent out-licensing to the pharmaceutical industry. A cocrystal is a crystalline entity in which more than one molecular substance is incorporated into the re...
